Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. 1985

P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts

The presence and synthesis of c-myc protein and mRNA in the cell cycle has been studied. We find that c-myc mRNA is present, at equivalent levels, at all times in the cell cycle with the possible exception of mitosis. Furthermore, we demonstrate that this mRNA is transcribed in both G1 and G2 phases. An analysis of the c-myc protein in vivo shows that de novo synthesis occurs in G1 and G2 and the protein turns over with a half-life of approximately 20-30 min in both phases. Furthermore, the level of c-myc protein rapidly increases in cell populations when they re-initiate the cell cycle, thereafter decreasing as the culture reaches quiescence. The results therefore suggest that expression of c-myc can be rapidly modulated and that it is activated during the G0 to G1 transition, but is expressed thereafter in the cell cycle.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009857 Oncogenes Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene. Transforming Genes,Oncogene,Transforming Gene,Gene, Transforming,Genes, Transforming
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide

Related Publications

P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts
January 1992, Current topics in microbiology and immunology,
P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts
February 1994, Cell biology international,
P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts
June 1994, Leukemia & lymphoma,
P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts
January 1985, Nature,
P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts
September 1994, Molecular and cellular biology,
P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts
December 1995, Fukushima journal of medical science,
P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts
January 2007, Journal of surgical oncology,
P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts
May 1990, Journal of cellular physiology,
P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts
March 1992, Cancer letters,
P H Rabbitts, and J V Watson, and A Lamond, and A Forster, and M A Stinson, and G Evan, and W Fischer, and E Atherton, and R Sheppard, and T H Rabbitts
January 1998, Oncology,
Copied contents to your clipboard!